Mezigdomide, Carfilzomib, and Dexamethasone

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
28 patients (estimated)
Sponsors
Roswell Park Cancer Institute
Tags
Cereblon E3 Ligase Modulators (CELMoDs)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2111
NCT Identifier
NCT06627751

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.